Given its status as the standard first-line therapy for advanced EGFR-mutant NSCLC, osimertinib is universally endorsed as a priority recommendation by leading global guidelines, including the National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), and Chinese Society of Clinical Oncology (CSCO)[3,18,19]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.